Brachial Artery t-PA Release in Heart Transplant Recipients
| Status: | Withdrawn |
|---|---|
| Conditions: | Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 7/16/2016 |
| Start Date: | October 2008 |
| End Date: | May 2011 |
Characterization of Brachial Arterial t-PA Release, Vasodilator Function, and Vascular Compliance and Correlation With Fibrinolytic Balance, Oxidative Stress, and Inflammation Measures in Heart Transplant Recipients (SCCOR Project 1, Aim 3C)
Bradykinin stimulates t-PA release from intact vessels, but not from endothelial cells in
culture. It has been proposed that the nerves of blood vessels are the source of bradykinin
stimulated t-PA release. In order tho test this hypothesis, we intend to infuse bradykinin
into the brachial (arm) artery and the coronary arteries of heart transplant recipients and
control subjects. This is because heart transplant recipients do not have nerves to their
coronary arteries.
This protocol studies the effects of bradykinin on t-PA release in the forearm of transplant
recipients. The brachial artery has intact nerves.
Separate protocols address coronary artery infusions in healthy subjects and transplant
recipients and forearm infusions in healthy subjects.
culture. It has been proposed that the nerves of blood vessels are the source of bradykinin
stimulated t-PA release. In order tho test this hypothesis, we intend to infuse bradykinin
into the brachial (arm) artery and the coronary arteries of heart transplant recipients and
control subjects. This is because heart transplant recipients do not have nerves to their
coronary arteries.
This protocol studies the effects of bradykinin on t-PA release in the forearm of transplant
recipients. The brachial artery has intact nerves.
Separate protocols address coronary artery infusions in healthy subjects and transplant
recipients and forearm infusions in healthy subjects.
Inclusion criteria:
1. Adults 18 years and greater who have undergone heart transplantation
2. Healthy
Exclusion criteria:
1. PVC < 30
2. Hypertensive subjects on ACE inhibitors
3. Pregnant or nursing mothers
4. Diabetic with HbA1C > 7.5 or stigmata of end organ damage (neuropathy, retinopathy,
nephropathy, cardiomyopathy)
5. Cholesterol > 30 mg/dL above NCEP accepted level based on cardiac risk.
6. Triglycerides > 200
7. Previously diagnosed obstructive coronary artery disease
8. Renal insufficiency (Creatinine ≥ 1.5 mg/dl)
9. History of cerebrovascular disease
10. Any chronic inflammatory disease (rheumatologic, inflammatory bowel disease, etc)
11. Uncontrolled Stage 2 Hypertension (160/100 mmHg), or end organ damage due to
hypertension (left ventricular hypertrophy, atrial fibrillation, hematuria, renal
insufficiency, prior cerebrovascular disease).
12. Angiotensin converting enzyme inhibitor use
13. Coagulopathy (INR ≥ 1.5, PTT ≥ 150% of control)
14. Peripheral Vascular Disease
15. Other chronic medical illnesses at the discretion of the investigators
We found this trial at
1
site
1211 Medical Center Dr
Nashville, Tennessee 37232
Nashville, Tennessee 37232
(615) 322-5000
Vanderbilt Univ Med Ctr Vanderbilt University Medical Center (VUMC) is a comprehensive healthcare facility dedicated...
Click here to add this to my saved trials
